Our 3rd annual March for Marrow 5K Run & Walk DC is in memory of Richard W. Carr and Ivan Fisher. Join us for a morning of fun, remembrance, and awareness at Hains Point! Festivities include team photos, awards, a memorial celebration, music, refreshments, inspirational speakers and a morning of fellowship with patients, families and friends affected by a
Join us for the 8th Annual March for Marrow 5K Run & Walk and help us find a cure for
Many hematologic malignancies are diseases of aging, and the use of hematopoietic cell transplant (HCT) is growing rapidly among older adults. Modern post-transplant
Thank you for attending the 2017 Patient and Family Conference in Orlando, FL.
Thank you for attending the 2017 Patient and Family Conference in Kansas City, MO.
On September 1, the Food and Drug Administration (FDA) approved gemtuzumab ozogamicin (Mylotarg™) for some patients with acute myeloid leukemia (AML).
The approval covers the use of gemtuzumab in adults with newly diagnosed AML that expresses a protein called CD33 (CD33-positive AML). The approval also covers the treatment of patients aged 2 and older with CD33-positive AML who have experienced a relapse or whose disease has not responded to initial treatment.
A genetic fault has been identified in people with an aggressive type of leukaemia that can significantly affect how they respond to treatment.